Insulet (NASDAQ:PODD) Shares Down 4.2% - Here's What Happened

Key Points

• Insulet Corporation's stock price fell by 4.2% to $318.35 from a previous close of $332.13, with trading volume significantly below average.
• Despite the recent decline, analysts maintain a consensus rating of "Moderate Buy" with a target price of $343.06, with numerous upgrades from major institutions.
• Insulet reported Q2 earnings of $1.17 per share, exceeding estimates, and showed a 32.9% year-over-year revenue increase to $649.1 million.

Shares of Insulet Corporation (NASDAQ:PODD - Get Free Report) were down 4.2% on Wednesday . The stock traded as low as $328.99 and last traded at $318.35. Approximately 18,380 shares traded hands during trading, a decline of 98% from the average daily volume of 743,112 shares. The stock had previously closed at $332.13.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PODD shares. Barclays boosted their price objective on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Raymond James Financial reiterated an "outperform" rating and issued a $360.00 price objective (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Royal Bank Of Canada boosted their target price on Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Truist Financial initiated coverage on Insulet in a report on Monday, June 16th. They set a "buy" rating and a $365.00 price objective on the stock. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $343.06.

Insulet Trading Down 0.8%

The business has a 50 day simple moving average of $315.14 and a two-hundred day simple moving average of $294.26. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market cap of $23.29 billion, a price-to-earnings ratio of 100.56, a price-to-earnings-growth ratio of 2.75 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently modified their holdings of PODD. Curi Capital LLC grew its holdings in shares of Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier's stock valued at $1,365,000 after buying an additional 36 shares in the last quarter. Evelyn Partners Investment Management Services Ltd grew its stake in Insulet by 28.7% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier's stock valued at $55,000 after purchasing an additional 39 shares in the last quarter. Camarda Financial Advisors LLC grew its stake in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier's stock valued at $2,304,000 after purchasing an additional 40 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Insulet by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier's stock valued at $634,000 after purchasing an additional 45 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV grew its stake in Insulet by 0.6% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock valued at $2,222,000 after purchasing an additional 48 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.